NO934270L - Fremstilling av magnetiske egenskaper til meget små magnetitt-dekstranpartikler - Google Patents
Fremstilling av magnetiske egenskaper til meget små magnetitt-dekstranpartiklerInfo
- Publication number
- NO934270L NO934270L NO934270A NO934270A NO934270L NO 934270 L NO934270 L NO 934270L NO 934270 A NO934270 A NO 934270A NO 934270 A NO934270 A NO 934270A NO 934270 L NO934270 L NO 934270L
- Authority
- NO
- Norway
- Prior art keywords
- particles
- magnetically responsive
- responsive material
- production
- magnetic properties
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Power Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Iron (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Hard Magnetic Materials (AREA)
Abstract
Partikler omfattende et magnetisk responsivt materiale, fortrinnsvis magnetitt, og et dispergerlngsmlddel, fortrinnsvis dekstran, hvor minst 90 £ av partiklene har et partlkkelstørrelsesområde fra ca 2 til ca 10 nm. Det beskrives også en fremgangsmåte for fremstilling av partiklene omfattende blanding av et magnetisk responsivt materiale med et dispergeringsmiddel for dannelse av en blanding, hensiktsmessig suspendert i en gelfase, og anbringelse av den første blandingen l kontakt med en base slik som ammoniumhydroksyd, i en tidsperiode og under betingelser som er hensiktsmessige for dannelse av en partikkel av magnetisk responsivt materiale og dispergeringsmiddel. Videre beskrives anvendelse av partiklene for en diagnosemetode omfattende administrasjon til et pattedyr av en kontrasteffektlv mengde av disse partiklene suspendert eller dlspergert i en fysiologisk tolererbar bærer med utvikling av et NMR-bilde av pattedyret.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/984,611 US5349957A (en) | 1992-12-02 | 1992-12-02 | Preparation and magnetic properties of very small magnetite-dextran particles |
Publications (2)
Publication Number | Publication Date |
---|---|
NO934270D0 NO934270D0 (no) | 1993-11-25 |
NO934270L true NO934270L (no) | 1994-06-03 |
Family
ID=25530702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO934270A NO934270L (no) | 1992-12-02 | 1993-11-25 | Fremstilling av magnetiske egenskaper til meget små magnetitt-dekstranpartikler |
Country Status (14)
Country | Link |
---|---|
US (1) | US5349957A (no) |
EP (1) | EP0600529A3 (no) |
JP (1) | JPH06218271A (no) |
KR (1) | KR940013542A (no) |
AU (1) | AU4747193A (no) |
CA (1) | CA2107280A1 (no) |
CZ (1) | CZ260193A3 (no) |
FI (1) | FI935302A (no) |
HU (1) | HUT69399A (no) |
IL (1) | IL107617A0 (no) |
MX (1) | MX9306009A (no) |
NO (1) | NO934270L (no) |
NZ (1) | NZ248701A (no) |
SK (1) | SK135093A3 (no) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021240A2 (de) * | 1993-03-17 | 1994-09-29 | Silica Gel Ges.M.B.H | Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben |
EP0713602B1 (en) * | 1993-08-12 | 2002-07-17 | Advanced Magnetics Incorporated | Use of polysaccharide covered superparamagnetic oxide colloids |
DE4428851C2 (de) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie |
ATE274341T1 (de) * | 1995-02-24 | 2004-09-15 | Elan Pharma Int Ltd | Nanopartikel-dispersionen enthaltende aerosole |
GB9600427D0 (en) * | 1996-01-10 | 1996-03-13 | Nycomed Imaging As | Contrast media |
ATE291439T1 (de) | 1996-01-10 | 2005-04-15 | Amersham Health As | Kontrastmittel |
US5855868A (en) * | 1996-04-01 | 1999-01-05 | Nycomed Imaging As | Method of T1 -weighted resonance imaging of RES organs |
US20050004049A1 (en) * | 1997-03-11 | 2005-01-06 | Elan Pharma International Limited | Novel griseofulvin compositions |
WO1999062079A1 (en) * | 1998-05-26 | 1999-12-02 | Bar-Ilan University | Nucleation and growth of magnetic metal oxide nanoparticles and its use |
US6315709B1 (en) * | 1998-08-07 | 2001-11-13 | Stereotaxis, Inc. | Magnetic vascular defect treatment system |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US20080213378A1 (en) * | 1998-10-01 | 2008-09-04 | Elan Pharma International, Ltd. | Nanoparticulate statin formulations and novel statin combinations |
US20090297602A1 (en) * | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
DE69939748D1 (de) | 1998-11-02 | 2008-11-27 | Elan Pharma Int Ltd | Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung |
US20070160675A1 (en) * | 1998-11-02 | 2007-07-12 | Elan Corporation, Plc | Nanoparticulate and controlled release compositions comprising a cephalosporin |
DE19921088C2 (de) * | 1999-04-30 | 2003-08-07 | Magforce Applic Gmbh | Stent zur Offenhaltung gangartiger Strukturen |
US7169618B2 (en) * | 2000-06-28 | 2007-01-30 | Skold Technology | Magnetic particles and methods of producing coated magnetic particles |
US20080241070A1 (en) * | 2000-09-21 | 2008-10-02 | Elan Pharma International Ltd. | Fenofibrate dosage forms |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7198795B2 (en) | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US6976647B2 (en) * | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
CA2451161A1 (en) * | 2001-06-22 | 2003-01-03 | Elan Pharma International, Ltd. | Method for high through put screening using a small scale mill or microfluidics |
PT1429731E (pt) * | 2001-09-19 | 2007-04-30 | Elan Pharma Int Ltd | Formulações de insulina nanoparticulada |
PT1443912E (pt) | 2001-10-12 | 2007-11-28 | Elan Pharma Int Ltd | Composições tendo uma combinação de características de libertação imediata e de libertação controlada |
EP1450863A4 (en) * | 2001-11-07 | 2009-01-07 | Imcor Pharmaceutical Company | PROCESS FOR IMAGING VESSELS WITH NANOTEHTIC CONTAINERS |
US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
ATE464880T1 (de) | 2002-02-04 | 2010-05-15 | Elan Pharma Int Ltd | Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator |
CA2479735C (en) * | 2002-03-20 | 2011-05-17 | Elan Pharma International Ltd. | Fast dissolving dosage forms having reduced friability |
WO2003081612A1 (en) * | 2002-03-26 | 2003-10-02 | Council Of Scientific And Industrial Research | Process for the preparation of nanosozed iron oxide by biomimetic route |
US20030185757A1 (en) * | 2002-03-27 | 2003-10-02 | Mayk Kresse | Iron-containing nanoparticles with double coating and their use in diagnosis and therapy |
WO2003082213A2 (en) * | 2002-03-28 | 2003-10-09 | Imcor Pharmaceutical Company | Compositions and methods for delivering pharmaceutically active agents using nanoparticulates |
US7462366B2 (en) * | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
US6800271B2 (en) * | 2002-04-01 | 2004-10-05 | Council Of Scientific And Industrial Research | Process for the preparation of nanosized iron oxide by biomimetic route |
WO2003086354A1 (en) | 2002-04-12 | 2003-10-23 | Elan Pharma International Ltd. | Nanoparticulate megestrol formulations |
US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
US9101540B2 (en) * | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
JP2005529911A (ja) * | 2002-05-06 | 2005-10-06 | エラン ファーマ インターナショナル,リミティド | ナノ粒子ナイスタチン製剤 |
US20070264348A1 (en) * | 2002-05-24 | 2007-11-15 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
CA2488498A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International Limited | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
EP2283864A1 (en) * | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
US7842377B2 (en) | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
CA2498207C (en) * | 2002-09-11 | 2012-03-13 | Elan Pharma International Ltd. | Gel-stabilized nanoparticulate active agent compositions |
US20040105778A1 (en) * | 2002-10-04 | 2004-06-03 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
US20040156895A1 (en) * | 2002-11-12 | 2004-08-12 | Elan Pharma International Ltd. | Solid dosage forms comprising pullulan |
WO2004058216A2 (en) * | 2002-12-17 | 2004-07-15 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
JP4469846B2 (ja) * | 2003-01-31 | 2010-06-02 | エラン ファーマ インターナショナル,リミティド | ナノ粒子状トピラメート製剤 |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
CA2523035C (en) * | 2003-05-22 | 2011-04-26 | Elan Pharma International Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
US7344491B1 (en) | 2003-11-26 | 2008-03-18 | Nanobiomagnetics, Inc. | Method and apparatus for improving hearing |
US8651113B2 (en) * | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
US7723311B2 (en) * | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
EP1651189B1 (en) * | 2003-08-08 | 2008-12-03 | Elan Pharma International Limited | Novel metaxalone compositions |
US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
JP4787165B2 (ja) * | 2003-11-05 | 2011-10-05 | エラン ファーマ インターナショナル,リミティド | 表面安定剤としてペプチドを有するナノ粒子組成物 |
FR2861994A1 (fr) * | 2003-11-12 | 2005-05-13 | Guerbet Sa | Nouvel agent de diagnostic pour l'irm dans les pathologies impliquant des proteinases |
US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
CN101106972A (zh) * | 2004-11-16 | 2008-01-16 | 伊兰制药国际有限公司 | 注射用纳米微粒奥氮平制剂 |
US20090155331A1 (en) * | 2005-11-16 | 2009-06-18 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
US8425550B2 (en) | 2004-12-01 | 2013-04-23 | Boston Scientific Scimed, Inc. | Embolic coils |
UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
KR20070116581A (ko) * | 2004-12-15 | 2007-12-10 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 타크롤리무스 제제 |
US20060159767A1 (en) * | 2004-12-22 | 2006-07-20 | Elan Pharma International Limited | Nanoparticulate bicalutamide formulations |
CN101132770A (zh) * | 2005-01-06 | 2008-02-27 | 伊兰制药国际有限公司 | 纳米微粒坎地沙坦制剂 |
KR100637275B1 (ko) | 2005-01-28 | 2006-10-23 | 한국지질자원연구원 | 초음파를 이용하여 제조된 mri 조영제에 사용되는산화철 나노분말 및 그 제조방법과 이를 이용한 mri조영제의 제조방법과 그 mri 조영제 |
EP2353590A1 (en) | 2005-02-15 | 2011-08-10 | Elan Pharma International Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
WO2006099121A2 (en) * | 2005-03-10 | 2006-09-21 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof |
JP2008533174A (ja) * | 2005-03-16 | 2008-08-21 | エラン ファーマ インターナショナル リミテッド | ナノ粒子ロイコトリエン受容体拮抗薬/副腎皮質ステロイド製剤 |
EA200701997A1 (ru) * | 2005-03-17 | 2008-02-28 | Элан Фарма Интернэшнл Лтд. | Композиция из наночастиц бисфосфоната |
JP2008534509A (ja) * | 2005-03-23 | 2008-08-28 | エラン ファーマ インターナショナル リミテッド | ナノ粒子副腎皮質ステロイドおよび抗ヒスタミン薬の製剤 |
BRPI0607537A2 (pt) * | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | formulações de derivado de quinazolina nanoparticulado |
WO2006110809A2 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
BRPI0609071A2 (pt) * | 2005-04-12 | 2010-11-16 | Elan Pharma Int Ltd | composicão estável de ciclosporina nanoparticulada, método para preparar uma ciclosporina nanoparticulada, uso da composição de ciclosporina nanoparticulada estável, e, composição de liberação controlada |
US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
WO2006132752A1 (en) * | 2005-05-10 | 2006-12-14 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising vitamin k2 |
JP2008540546A (ja) * | 2005-05-10 | 2008-11-20 | エラン ファーマ インターナショナル リミテッド | ナノ粒子クロピドグレル製剤 |
EA015102B1 (ru) * | 2005-06-03 | 2011-06-30 | Элан Фарма Интернэшнл Лтд. | Препараты наночастиц мезилата иматиниба |
WO2006133045A1 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
US20060292214A1 (en) * | 2005-06-03 | 2006-12-28 | Elan Pharma International Limited | Nanoparticulate acetaminophen formulations |
JP2009517485A (ja) | 2005-06-08 | 2009-04-30 | エラン・ファルマ・インターナショナル・リミテッド | セフジトレンを含むナノ粒子状および制御放出組成物 |
DE602006010070D1 (de) * | 2005-06-09 | 2009-12-10 | Elan Pharma Int Ltd | Nanopartikuläre ebastinformulierungen |
EA200800041A1 (ru) * | 2005-06-13 | 2008-04-28 | Элан Фарма Интернэшнл Лтд. | Составы с наночастицами клопидогреля, содержащие комбинацию клопидогреля и аспирина |
US20100221327A1 (en) * | 2005-06-15 | 2010-09-02 | Elan Pharma International Limited | Nanoparticulate azelnidipine formulations |
US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
US20070015719A1 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International Limited | Nanoparticulate clarithromycin formulations |
JP2009507925A (ja) * | 2005-09-13 | 2009-02-26 | エラン ファーマ インターナショナル リミテッド | ナノ粒子タダラフィル製剤 |
EP2279727A3 (en) | 2005-09-15 | 2011-10-05 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
US8007509B2 (en) | 2005-10-12 | 2011-08-30 | Boston Scientific Scimed, Inc. | Coil assemblies, components and methods |
US8152839B2 (en) | 2005-12-19 | 2012-04-10 | Boston Scientific Scimed, Inc. | Embolic coils |
US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
EP2077731B1 (en) * | 2006-01-17 | 2011-08-31 | Philip Morris Products S.A. | Cigarette components having encapsulated catalyst particles and methods of making and use thereof |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
MX2008015275A (es) * | 2006-05-30 | 2009-02-06 | Elan Pharma Int Ltd | Formulaciones de posaconazol en nanoparticulas. |
JP2009543797A (ja) * | 2006-07-10 | 2009-12-10 | エラン ファーマ インターナショナル,リミティド | ナノ粒子ソラフェニブ製剤 |
US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
US20090238867A1 (en) * | 2007-12-13 | 2009-09-24 | Scott Jenkins | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same |
JP2011520779A (ja) * | 2008-03-21 | 2011-07-21 | エラン・ファルマ・インターナショナル・リミテッド | イマチニブの部位特異的送達のための組成物および使用の方法 |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
WO2010099508A1 (en) | 2009-02-26 | 2010-09-02 | Theraquest Biosciences, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
FR2945950A1 (fr) | 2009-05-27 | 2010-12-03 | Elan Pharma Int Ltd | Compositions de nanoparticules anticancereuses et procedes pour les preparer |
JP6072539B2 (ja) | 2009-05-27 | 2017-02-01 | アルカーメス ファーマ アイルランド リミテッド | ナノ粒子活性物質組成物におけるフレーク状凝集の軽減 |
EP3288957A4 (en) | 2015-05-01 | 2019-01-23 | Cocrystal Pharma, Inc. | NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5913521B2 (ja) * | 1975-06-19 | 1984-03-30 | メイトウサンギヨウ カブシキガイシヤ | 磁性酸化鉄・デキストラン複合体の製造法 |
US4735796A (en) * | 1983-12-08 | 1988-04-05 | Gordon Robert T | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
US4975282A (en) * | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
US4795698A (en) * | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
US5219554A (en) * | 1986-07-03 | 1993-06-15 | Advanced Magnetics, Inc. | Hydrated biodegradable superparamagnetic metal oxides |
US4827945A (en) * | 1986-07-03 | 1989-05-09 | Advanced Magnetics, Incorporated | Biologically degradable superparamagnetic materials for use in clinical applications |
US5055288A (en) * | 1987-06-26 | 1991-10-08 | Advanced Magnetics, Inc. | Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides |
US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
JP2726520B2 (ja) * | 1989-10-20 | 1998-03-11 | 名糖産業株式会社 | 有機磁性複合体 |
-
1992
- 1992-12-02 US US07/984,611 patent/US5349957A/en not_active Expired - Fee Related
-
1993
- 1993-09-20 NZ NZ248701A patent/NZ248701A/en unknown
- 1993-09-21 AU AU47471/93A patent/AU4747193A/en not_active Abandoned
- 1993-09-28 MX MX9306009A patent/MX9306009A/es unknown
- 1993-09-29 CA CA002107280A patent/CA2107280A1/en not_active Abandoned
- 1993-10-29 KR KR1019930022699A patent/KR940013542A/ko not_active Application Discontinuation
- 1993-11-08 JP JP5278122A patent/JPH06218271A/ja active Pending
- 1993-11-12 EP EP93203162A patent/EP0600529A3/en not_active Withdrawn
- 1993-11-15 IL IL10761793A patent/IL107617A0/xx unknown
- 1993-11-25 NO NO934270A patent/NO934270L/no unknown
- 1993-11-29 FI FI935302A patent/FI935302A/fi not_active Application Discontinuation
- 1993-12-01 SK SK1350-93A patent/SK135093A3/sk unknown
- 1993-12-01 CZ CZ932601A patent/CZ260193A3/cs unknown
- 1993-12-02 HU HU9303415A patent/HUT69399A/hu unknown
Also Published As
Publication number | Publication date |
---|---|
EP0600529A2 (en) | 1994-06-08 |
IL107617A0 (en) | 1994-02-27 |
NO934270D0 (no) | 1993-11-25 |
CA2107280A1 (en) | 1994-06-03 |
CZ260193A3 (en) | 1994-08-17 |
FI935302A0 (fi) | 1993-11-29 |
HU9303415D0 (en) | 1994-03-28 |
EP0600529A3 (en) | 1995-10-25 |
HUT69399A (en) | 1995-09-28 |
US5349957A (en) | 1994-09-27 |
MX9306009A (es) | 1995-01-31 |
SK135093A3 (en) | 1994-09-07 |
NZ248701A (en) | 1995-09-26 |
AU4747193A (en) | 1994-06-16 |
FI935302A (fi) | 1994-06-03 |
JPH06218271A (ja) | 1994-08-09 |
KR940013542A (ko) | 1994-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO934270L (no) | Fremstilling av magnetiske egenskaper til meget små magnetitt-dekstranpartikler | |
Guzman et al. | Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI | |
Schonbrunn et al. | Epidermal growth factor and thyrotropin-releasing hormone act similarly on a clonal pituitary cell strain. Modulation of hormone production and inhibition of cell proliferation | |
EP0474785A4 (en) | Percutaneous lymphography | |
Goridis et al. | Rapid, light-induced changes of retinal cyclic GMP levels | |
Tischler et al. | Long-term effects of dexamethasone and nerve growth factor on adrenal medullary cells cultured from young adult rats | |
NO173429C (no) | Anvendelse av ferromagnetiske partikler i kontrastmidler for NMR-avbildning | |
Schlegel et al. | Thyrotropin-releasing hormone increases cytosolic free Ca2+ in clonal pituitary cells (GH3 cells): direct evidence for the mobilization of cellular calcium. | |
DE59406230D1 (de) | Präparat zur durchblutungsförderung das hartmagnetische teilchen enthält | |
JPS6435372A (en) | Immunoassay method using colloidal non- metal particle | |
NO932320L (no) | Fremgangsmaate for paavisning av en analytt i en proeve og et utstyrsett for denne | |
Ho et al. | Sex-related differences in GH secretion in rat using reverse hemolytic plaque assay | |
Davies et al. | Short‐and long‐term evaluation of normal and abnormal human thyroid cells in monolayer culture | |
Karzai et al. | Regulation of the synthesis and secretion of transferrin and cyclic protein-2/cathepsin L by mature rat Sertoli cells in culture | |
Overton | Selective formation of desmosomes in chick cell reaggregates | |
Kupchik et al. | A new method for the three-dimensional in vitro growth of human cancer cells | |
Schechter | A light and electron microscopic study of Rathke's pouch in fetal rabbits | |
Kammerman et al. | Gonadotropin receptors in experimentally induced ovarian tumors in mice | |
ES8705650A1 (es) | Procedimiento para preparar pigmentos magenticos coloreados. | |
ATE77223T1 (de) | Speiseroehren-sonde mit mess- oder stimulationselektroden. | |
Sacks et al. | Retinoic acid inhibition of a head and neck multicellular tumor spheroid model | |
Davies et al. | Thyroglobulin secretion by human thyroid cells after monolayer culture–comparison of normal and adenomatous cells | |
Raben et al. | Relationship of thrombin‐stimulated arachidonic acid release and metabolism to mitogenesis and phosphatidylinositol synthesis | |
Loughney et al. | Menstrual cycle related differences in the proliferative responses of cultured human endometrial stromal cells to retinoic acid | |
De Weger et al. | [29] Cytotoxicity by macrophages and monocytes |